Skip to main content
main-content
Top

02-07-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

LISTEN: How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti (9:04).

Related topics

CME-accredited webcast

Learn more about real-world evidence of new GLP-1RAs with Melanie Davies, Stewart Harris & Takashi Kadowaki

Image Credits